Navigation Links
Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
Date:9/5/2007

ding Canada and Mexico) and India.

In addition, Spectrum will receive 50 percent of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan. Japanese rights for all potential oncology indications have recently been licensed to Nippon Kayaku, a key player in the Japanese oncology market.

Spectrum is developing ozarelix for benign prostatic hypertrophy (BPH), hormone-dependent prostate cancer and other indications.

About Benign Prostatic Hypertrophy

Benign prostatic hypertrophy is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70 and it is estimated that there are currently more than 28 million men suffering from BPH in the United States.

The IPSS (also known as AUA symptom index) is a standardized scoring system that evaluates the seven principal symptoms of BPH. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options have limited efficacy, leading to inadequate compliance. Medications currently available belong to two classes: alpha blockers (such as FLOMAX(R)[1], CARDURA(R)[2] and HYTRIN(R)[3]) which relax the muscles in the neck of the bladder and in the prostate, but have no direct effect on the prostate growth itself, and alpha reductase inhibitors (such as PROSCAR(R)[4] and AVODART(R)[5]), which can result in some reduction of the prostate size but have a very slow onset of action, and may be associated with impotence and decreased libido.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidate
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources Group finds ... Australia , China , ... Korea—will expand at a strong rate through 2023. Dental implant procedure ... and as patient awareness rises. Other key findings from ... dental implant market: , Dental implant penetration: ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... ANGELES , Sept. 30, 2014   Easy ... shopping destination , today announced that it now offers ... . AirSense CPAPs are the first sleep apnea therapy ... it simple and easy to track and share real-time ... overall effectiveness of their CPAP therapy.  In addition, the ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... 2011 Endologix, Inc. (NASDAQ: ELGX ), developer ... financial results for the three and six months ended June ... Executive Officer, said, "We are pleased with our progress during ... and new product development goals for 2011.  In the second ...
... July 21, 2011 Cardiac Science Corporation ... (AEDs) and diagnostic cardiac monitoring devices that connect ... systems, announced today the new capability of direct ... and the GE Healthcare Centricity® EMR system. ...
Cached Medicine Technology:Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9Cardiac Science Expands Device Connectivity Solutions 2Cardiac Science Expands Device Connectivity Solutions 3
(Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... that is helping people perform better in and out of ... performance, and memory has caught the attention of Shane Michaels, ... the day-to-day grind, fatigue is the reason most people simply ... want, whether that means staying focused at work, getting the ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... providers in Turkey has gone up more than 79 ... The medical tourism company also reported total revenue tripled ... 2012. , The company’s professional strategy has allowed them ... — ultimately designed for patient comfort and privacy — ...
(Date:9/30/2014)... September 30, 2014 Hospice & ... annual “In Celebration” gala, honoring three outstanding individuals ... of striving to provide extraordinary and dignified comfort, ... a serious or life-limiting illness. , The event ... Rye, NY and recognized William (Bill) J. McGuinness, ...
(Date:9/30/2014)... 30, 2014 Regenerative Medicine Solutions (RMS) ... clinics in Nashville, Tennessee. RMS welcomes the launch of ... the expansion of a new treatment center for the ... Sleep Apnea Institute to Nashville, the hope is to ... apnea: both diagnosed and undiagnosed. With Nashville being a ...
Breaking Medicine News(10 mins):Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Regenerative Medicine Solutions Expanding 2
... All 90 Inspected Pennsylvania Facilities Meet Federal StandardsHARRISBURG, ... Protection released reports today showing that all of ... fourth quarter of 2008 are operating within the ... Drug Administration.DEP inspects each of Pennsylvania,s approximately 400 ...
... The annual Bio-IT World Conference & Expo will be held April 27-29, ... debut in 2002, the Expo has established itself as the premier event ... the drug discovery enterprise. The Expo is the perfect place to ... ...
... (Nasdaq: MYL ) today announced that its Vice ... NASDAQ Stock Market opening on Friday, Feb. 20 from 9:15 ... to celebrate the company,s switch from The New York Stock ... Dec. 29, 2008. The company is listed on the NASDAQ ...
... cadherin superfamily has a correlate relationship with the ... suggested that, unlike E-cadherin, N-cadherin may promote motility ... pathological significance of E-cadherin and N-cadherin expressions in ... led by Prof. Qing-Xia Fan from China detected ...
... low-dose aspirin-induced peptic ulcer seems to be increasing in ... individuals, in whom metabolic syndrome frequently develops. However, a ... not yet been established. , A research team led ... Their study will be published on February 14, 2009 ...
... are defined as leading an active or inactive lifestyle ... which guideline your GP picks off the shelf, say ... countries have guidelines recommending the minimum amount of physical ... of this advice is conflicting, making it difficult for ...
Cached Medicine News:Health News:PA DEP Releases Quarterly Mammography Inspections 2Health News:PA DEP Releases Quarterly Mammography Inspections 3Health News:PA DEP Releases Quarterly Mammography Inspections 4Health News:Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine 2Health News:Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine 3Health News:Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell 2Health News:What is the most effective therapy for low-dose aspirin induced peptic ulcer? 2Health News:Physical activity guidelines are too confusing, say researchers 2
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... Katena Products, Inc. is ... company dedicated exclusively to ophthalmic ... products to over 7,000 customers ... through a global network of ...
... food, exercise, stress . . . Theyre ... overall health. Unfortunately, its difficult, and often ... on a daily basis. Its even more ... submit the information to a care provider ...
... Managing diabetes requires making decisions about insulin ... exercise. These decisions are guided by data ... information, and by the patterns that can ... Care Providers when the data is presented ...
Medicine Products: